AH Equity Partners Bio I, L.L.C. bought $8.0M of CAMP4 THERAPEUTICS (CAMP)
Executed Oct 15 2024, disclosed Oct 17 2024, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Oct 17 2024), the stock returned -7.3% (delay-adjusted); from the execution session (Oct 15 2024), +20.8%. Derived: entry at the session's open, exit at the close 20 sessions later.
AH Equity Partners Bio I, L.L.C. (10% owner) filed 1 Form 4 report as a reporting entity in the past 24 months (1 purchase, 0 sales), most often in CAMP4 THERAPEUTICS CORPORATION (CAMP). Across 1 priced purchase filing, the average 21-session return was +20.8% from execution and -7.3% from disclosure (delay-adjusted; derived). The largest single filing was $8.0M of CAMP (727,272 sh across 2 lots, as filed), executed Oct 15 2024.
Healthcare · Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→